Relay Therapeutics Inc
NASDAQ:RLAY
Intrinsic Value
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. [ Read More ]
The intrinsic value of one RLAY stock under the Base Case scenario is 0.428 USD. Compared to the current market price of 6.155 USD, Relay Therapeutics Inc is Overvalued by 93%.
Valuation Backtest
Relay Therapeutics Inc
Run backtest to discover the historical profit from buying and selling RLAY stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Relay Therapeutics Inc
Current Assets | 770.1m |
Cash & Short-Term Investments | 750.1m |
Other Current Assets | 20m |
Non-Current Assets | 73.9m |
PP&E | 68.9m |
Intangibles | 2.3m |
Other Non-Current Assets | 2.7m |
Current Liabilities | 30.3m |
Accounts Payable | 9.2m |
Accrued Liabilities | 19.9m |
Other Current Liabilities | 1.2m |
Non-Current Liabilities | 61.7m |
Other Non-Current Liabilities | 61.7m |
Earnings Waterfall
Relay Therapeutics Inc
Revenue
|
25.5m
USD
|
Operating Expenses
|
-398.5m
USD
|
Operating Income
|
-373m
USD
|
Other Expenses
|
31m
USD
|
Net Income
|
-342m
USD
|
Free Cash Flow Analysis
Relay Therapeutics Inc
RLAY Profitability Score
Profitability Due Diligence
Relay Therapeutics Inc's profitability score is 11/100. The higher the profitability score, the more profitable the company is.
Score
Relay Therapeutics Inc's profitability score is 11/100. The higher the profitability score, the more profitable the company is.
RLAY Solvency Score
Solvency Due Diligence
Relay Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Relay Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RLAY Price Targets Summary
Relay Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for RLAY is 23.516 USD with a low forecast of 10.706 USD and a high forecast of 34.65 USD.
Ownership
RLAY Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
RLAY Price
Relay Therapeutics Inc
Average Annual Return | -19.37% |
Standard Deviation of Annual Returns | 34.45% |
Max Drawdown | -90% |
Market Capitalization | 784.5m USD |
Shares Outstanding | 131 179 000 |
Percentage of Shares Shorted | 10.96% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 245 full-time employees. The company went IPO on 2020-07-16. The firm is focused on transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The firm is advancing a pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008, RLY-2608 and RLY-1971. Its RLY-1971 binds and stabilizes Src homology region two (SH2)-containing protein tyrosine phosphatase two (SHP2) in its inactive conformation. Its RLY-4008, is it inhibitor of fibroblast growth factor receptor 2 (FGFR2), enriched for patients with advanced solid tumors having oncogenic FGFR2. The firm uses its Dynamo platform to focus on precision oncology. The company is also advancing several early programs focused on other precision oncology and genetic disease targets.
Contact
IPO
Employees
Officers
The intrinsic value of one RLAY stock under the Base Case scenario is 0.428 USD.
Compared to the current market price of 6.155 USD, Relay Therapeutics Inc is Overvalued by 93%.